{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:23:53Z","timestamp":1779243833153,"version":"3.51.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40268-020-00320-5","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T08:02:39Z","timestamp":1600761759000},"page":"319-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-3244","authenticated-orcid":false,"given":"Chrissy","family":"Bolton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Hawthorne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ianthe R. M.","family":"Schepel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elinor","family":"Harriss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke C.","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Wace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"key":"320_CR1","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1038\/s41436-018-0026-4","volume":"20","author":"MA Giovanni","year":"2018","unstructured":"Giovanni MA, Murray MF. Genome-first findings require precision phenotyping. Genet Med. 2018;20:1510\u20131.","journal-title":"Genet Med"},{"key":"320_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/msb4100163","volume":"3","author":"J Loscalzo","year":"2007","unstructured":"Loscalzo J, Kohane I, Barabasi A-L. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol. 2007;3:124.","journal-title":"Mol Syst Biol"},{"key":"320_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/gb4175","volume":"15","author":"IS Kohane","year":"2014","unstructured":"Kohane IS. Deeper, longer phenotyping to accelerate the discovery of the genetic architectures of diseases. Genome Biol. 2014;15:115.","journal-title":"Genome Biol"},{"key":"320_CR4","doi-asserted-by":"publisher","first-page":"a000372","DOI":"10.1101\/mcs.a000372","volume":"1","author":"PN Robinson","year":"2015","unstructured":"Robinson PN, Mungall CJ, Haendel M. Capturing phenotypes for precision medicine. Cold Spring Harb Mol Case Stud. 2015;1:a000372.","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"320_CR5","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ajhg.2008.09.017","volume":"83","author":"PN Robinson","year":"2008","unstructured":"Robinson PN, K\u00f6hler S, Bauer S, et al. The human phenotype ontology: a tool for annotating and analyzing human hereditary disease. Am J Hum Genet. 2008;83:610\u20135.","journal-title":"Am J Hum Genet"},{"key":"320_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12016-017-8627-2","volume":"53","author":"S Ribero","year":"2017","unstructured":"Ribero S, Sciascia S, Borradori L, et al. The cutaneous spectrum of lupus erythematosus. Clin Rev Allergy Immunol. 2017;53:291\u2013305.","journal-title":"Clin Rev Allergy Immunol"},{"key":"320_CR7","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/acr.22502","volume":"67","author":"S Jarukitsopa","year":"2015","unstructured":"Jarukitsopa S, Hoganson DD, Crowson CS, et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. Arthritis Care Res (Hoboken). 2015;67:817\u201328.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"320_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0733-8635(02)00016-5","volume":"20","author":"P Patel","year":"2002","unstructured":"Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin. 2002;20:373\u201385.","journal-title":"Dermatol Clin"},{"key":"320_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1159\/000246716","volume":"190","author":"T Watanabe","year":"1995","unstructured":"Watanabe T, Tsuchida T. Classification of lupus erythematosus based upon cutaneous manifestations. Dermatology. 1995;190:277\u201383.","journal-title":"Dermatology"},{"key":"320_CR10","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/archderm.1979.04010120007006","volume":"115","author":"RD Sontheimer","year":"1979","unstructured":"Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol. 1979;115:1409\u201315.","journal-title":"Arch Dermatol"},{"key":"320_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/jid.2014.316","volume":"135","author":"HY Schultz","year":"2015","unstructured":"Schultz HY, Dutz JP, Furukawa F, et al. From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd international conference on cutaneous lupus erythematosus (ICCLE) 2013. J Investig Dermatol. 2015;135:7\u201312.","journal-title":"J Investig Dermatol"},{"key":"320_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/archderm.139.1.45","volume":"139","author":"M Srivastava","year":"2003","unstructured":"Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro\/SSA-positive cutaneous lupus erythematosus. Arch Dermatol. 2003;139:45\u20139.","journal-title":"Arch Dermatol"},{"key":"320_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00403-008-0890-x","volume":"301","author":"RD Sontheimer","year":"2009","unstructured":"Sontheimer RD, Henderson CL, Grau RH, et al. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res. 2009;301:65\u201370.","journal-title":"Arch Dermatol Res"},{"key":"320_CR14","first-page":"465","volume":"164","author":"G Lowe","year":"2011","unstructured":"Lowe G, Henderson CL, Grau RH, et al. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011;164:465\u201372.","journal-title":"Br J Dermatol"},{"key":"320_CR15","doi-asserted-by":"publisher","first-page":"13030\/qt55x4282","DOI":"10.5070\/D3233034281","volume":"23","author":"TC Michaelis","year":"2017","unstructured":"Michaelis TC, Sontheimer RD, Lowe GC. An update in drug-induced subacute cutaneous lupus erythematosus. Dermatol Online J. 2017;23:13030\/qt55x42822.","journal-title":"Dermatol Online J"},{"key":"320_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.7326\/0003-4819-103-1-49","volume":"103","author":"BR Reed","year":"1985","unstructured":"Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985;103:49\u201351.","journal-title":"Ann Intern Med"},{"issue":"6","key":"320_CR17","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/rheumatology\/kez502","volume":"59","author":"C Bolton","year":"2020","unstructured":"Bolton C, Mouyis K, Bhamra K, et al. The first case of natalizumab-induced subacute cutaenous lupus erythematosus. Rheumatology. 2020;59(6):1446\u20137.","journal-title":"Rheumatology"},{"key":"320_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.autrev.2009.02.022","volume":"8","author":"A Kuhn","year":"2009","unstructured":"Kuhn A, Kuehn E, Meuth AM, et al. Development of a Core Set Questionnaire by the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2009;8:702\u201312.","journal-title":"Autoimmun Rev"},{"key":"320_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.autrev.2004.10.003","volume":"4","author":"RD Sontheimer","year":"2005","unstructured":"Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev. 2005;4:253\u201363.","journal-title":"Autoimmun Rev"},{"key":"320_CR20","first-page":"305","volume-title":"Dubois\u2019 lupus erythematosus and related syndromes","author":"AA Sinha","year":"2018","unstructured":"Sinha AA, Dey-Rao R. Pathogenesis of cutaneous lupus. In: Wallace DJ, Hahn BH, Crow MK, et al., editors. Dubois\u2019 lupus erythematosus and related syndromes. Philadelphia: Elsevier; 2018. p. 305\u2013316."},{"key":"320_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0049-0172(75)90024-4","volume":"5","author":"S Lee","year":"1975","unstructured":"Lee S, Harvey CP. Drug-induced systemic lupus erythematosus: a critical review. Semin Arthritis Rheum. 1975;5:83\u2013103.","journal-title":"Semin Arthritis Rheum"},{"key":"320_CR22","unstructured":"European Workshop on Skin Immune Mediated Inflammatory Diseases (SIMID). Conference abstracts\u2014European workshop on SIMID. Verona, 24\u201326 April 2014, p 1\u201382."},{"key":"320_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/19420862.2015.989042","volume":"7","author":"DM Ecker","year":"2015","unstructured":"Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7:9\u201314.","journal-title":"MAbs"},{"key":"320_CR24","doi-asserted-by":"crossref","unstructured":"Philippidis A. Top 15 best-selling drugs of 2018. Genetic engineering and biotechnology news. 2019. https:\/\/www.genengnews.com\/a-lists\/top-15-best-selling-drugs-of-2018\/. Accessed 29 July 2019.","DOI":"10.1089\/genedge.1.1.05"},{"key":"320_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrd.2018.42","volume":"17","author":"L Urquhart","year":"2018","unstructured":"Urquhart L. Top drugs and companies by sales in 2017. Nat Rev Drug Discov. 2018;17:232\u2013232.","journal-title":"Nat Rev Drug Discov"},{"key":"320_CR26","unstructured":"Office of the Assistant Secretary for Planning and Evaluation. Comparison of US and international prices for top medicare part b drugs by total expenditures. 2018. https:\/\/aspe.hhs.gov\/system\/files\/pdf\/259996\/ComparisonUSInternationalPricesTopSpendingPartBDrugs.pdf.\u00a0Accessed 30 July 2019."},{"key":"320_CR27","first-page":"109","volume":"24","author":"I Hernandez","year":"2018","unstructured":"Hernandez I, Bott SW, Patel AS, et al. Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care. 2018;24:109\u201312.","journal-title":"Am J Manag Care"},{"key":"320_CR28","unstructured":"America\u2019s Health Insurance Plans. High-price drugs based upon estimated annual per-patient expenditure high-priced drugs: estimates of annual per-patient expenditures for 150 specialty medications. 2016. https:\/\/www.ahip.org\/wp-content\/uploads\/2016\/04\/HighPriceDrugsReport.pdf. Accessed 27 May 2020."},{"key":"320_CR29","unstructured":"National Institute for Health and Clinical Excellence. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. NICE Guidance 2010. Technology appraisal guidance [TA199]."},{"key":"320_CR30","doi-asserted-by":"publisher","first-page":"S242","DOI":"10.1016\/j.jaad.2005.10.037","volume":"54","author":"DD Bentley","year":"2006","unstructured":"Bentley DD, Graves JE, Smith DI, et al. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2006;54:S242\u2013S243243.","journal-title":"J Am Acad Dermatol"},{"key":"320_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/1752-1947-5-243","volume":"5","author":"P Vihinen","year":"2011","unstructured":"Vihinen P, Paija O, Kivisaari A, et al. Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report. J Med Case Rep. 2011;5:243.","journal-title":"J Med Case Rep"},{"key":"320_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/0961203313517153","volume":"23","author":"A Brunasso","year":"2014","unstructured":"Brunasso A, Aberer W, Massone C, et al. Subacute lupus erythematosus during treatment with golimumab for seronegative rheumatoid arthritis. Lupus. 2014;23:201\u20133.","journal-title":"Lupus"},{"key":"320_CR33","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bjd.17245","volume":"181","author":"AL Marano","year":"2019","unstructured":"Marano AL, Clarke JM, Morse MA, et al. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. Br J Dermatol. 2019;181:580\u20133.","journal-title":"Br J Dermatol"},{"key":"320_CR34","first-page":"1308","volume":"56","author":"M Cura","year":"2017","unstructured":"Cura M. TNFalpha inhibitor induced lupus-like syndrome. Int J Dermatol. 2017;56:1308\u20139.","journal-title":"Int J Dermatol"},{"key":"320_CR35","doi-asserted-by":"publisher","first-page":"752","DOI":"10.4103\/0301-4738.121133","volume":"61","author":"M Andric","year":"2013","unstructured":"Andric M, Dixit S, Robaei D, et al. A case of subacute cutaneous lupus erythematosus as a result of ranibizumab (Lucentis) treatment. Indian J Ophthalmol. 2013;61:752.","journal-title":"Indian J Ophthalmol"},{"key":"320_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jaut.2014.01.021","volume":"48\u201349","author":"A Kuhn","year":"2014","unstructured":"Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;48\u201349:14\u20139.","journal-title":"J Autoimmun"},{"key":"320_CR37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/1523-1747.ep12616582","volume":"99","author":"KM David-Bajar","year":"1992","unstructured":"David-Bajar KM, Bennion SD, DeSpain JD, et al. Clinical, histologic, and immunofluorescent distinctions between subacute cutaneous lupus erythematosus and discoid lupus erythematosus. J Investig Dermatol. 1992;99:251\u20137.","journal-title":"J Investig Dermatol"},{"key":"320_CR38","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/jid.2009.42","volume":"129","author":"RD Sontheimer","year":"2009","unstructured":"Sontheimer RD. Lichenoid tissue reaction\/interface dermatitis: clinical and histological perspectives. J Investig Dermatol. 2009;129:1088\u201399.","journal-title":"J Investig Dermatol"},{"key":"320_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0151-9638(05)79281-4","volume":"132","author":"C-M Vabre-Latre","year":"2005","unstructured":"Vabre-Latre C-M, Bayle P, Marguery M-C, et al. Worsening of subacute lupus erythematosus induced by infliximab [in French]. Ann Dermatol Venereol. 2005;132:349\u201353.","journal-title":"Ann Dermatol Venereol"},{"key":"320_CR40","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1001\/archderm.137.9.1196","volume":"137","author":"JP Callen","year":"2001","unstructured":"Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine. Arch Dermatol. 2001;137:1196\u20138.","journal-title":"Arch Dermatol"},{"key":"320_CR41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2230.2004.01498.x","volume":"29","author":"GK Perera","year":"2004","unstructured":"Perera GK, Black MM, McGibbon DH. Bullous subacute cutaneous lupus erythematosus. Clin Exp Dermatol. 2004;29:265\u20137.","journal-title":"Clin Exp Dermatol"},{"key":"320_CR42","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.mayocp.2016.10.030","volume":"92","author":"DT Alniemi","year":"2017","unstructured":"Alniemi DT, Gutierrez A, Drage LA, et al. Subacute cutaneous lupus erythematosus. Mayo Clin Proc. 2017;92:406\u201314.","journal-title":"Mayo Clin Proc"},{"key":"320_CR43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1365-2133.2011.10397.x","volume":"165","author":"AV Marzano","year":"2011","unstructured":"Marzano AV, Lazzari R, Polloni I, et al. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol. 2011;165:335\u201341.","journal-title":"Br J Dermatol"},{"key":"320_CR44","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1365-2133.2012.10969.x","volume":"167","author":"CM Gr\u00f6nhagen","year":"2012","unstructured":"Gr\u00f6nhagen CM, Fored CM, Linder M, et al. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012;167:296\u2013305.","journal-title":"Br J Dermatol"},{"key":"320_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1684\/ejd.2016.2912","volume":"27","author":"R Laurinaviciene","year":"2017","unstructured":"Laurinaviciene R, Sandholdt LH, Bygum A. Drug-induced cutaneous lupus erythematosus: 88 new cases. Eur J Dermatol. 2017;27:28\u201333.","journal-title":"Eur J Dermatol"},{"key":"320_CR46","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.autrev.2012.08.019","volume":"12","author":"C Biazar","year":"2013","unstructured":"Biazar C, Sigges J, Patsinakidis N, et al. Cutaneous lupus erythematosus: First multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2013;12:444\u201354.","journal-title":"Autoimmun Rev"},{"key":"320_CR47","first-page":"889","volume":"10","author":"C Dalle Vedove","year":"2012","unstructured":"Dalle Vedove C, Simon JC, Girolomoni G. Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNF\u03b1 agents. J der Dtsch Dermatologischen Gesellschaft. 2012;10:889\u201397.","journal-title":"J der Dtsch Dermatologischen Gesellschaft"},{"key":"320_CR48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.semarthrit.2007.08.003","volume":"37","author":"MF Costa","year":"2008","unstructured":"Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor \u03b1 agents. Semin Arthritis Rheum. 2008;37:381\u20137.","journal-title":"Semin Arthritis Rheum"},{"key":"320_CR49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1590\/abd1806-4841.20153834","volume":"90","author":"CF Amarante","year":"2015","unstructured":"Amarante CF, Acedo LMS, de Rabay FMO, et al. Drug-induced lupus with leukocytoclastic vasculitis: a rare expression associated with adalimumab. An Bras Dermatol. 2015;90:121\u20134.","journal-title":"An Bras Dermatol"},{"key":"320_CR50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1346-8138.2012.01624.x","volume":"39","author":"H Jee","year":"2012","unstructured":"Jee H, Kim S, Kim D, et al. Atypical cutaneous manifestation of lupus-like syndrome after etanercept treatment in seropositive rheumatoid arthritis: P17\u201342. J Dermatol. 2012;39:53\u2013280.","journal-title":"J Dermatol"},{"key":"320_CR51","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/j.jaad.2010.06.017","volume":"65","author":"A Kuhn","year":"2011","unstructured":"Kuhn A, Ruland V, Bonsmann G, et al. Cutaneous lupus erythematosus: update of therapeutic options: part II. J Am Acad Dermatol. 2011;65:e195\u2013e213.","journal-title":"J Am Acad Dermatol"},{"key":"320_CR52","unstructured":"U.S National Library of Medicine. Search of: subacute cutaneous lupus\u2014List Results\u2014ClinicalTrials.gov. 2019. https:\/\/clinicaltrials.gov\/ct2\/results?cond=subacute+cutaneous+lupus&term=&cntry=&state=&city=&dist=&Search=Search. Accessed 23 July 2019."},{"key":"320_CR53","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00228-007-0421-2","volume":"64","author":"TG Tzellos","year":"2008","unstructured":"Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol. 2008;64:337\u201341.","journal-title":"Eur J Clin Pharmacol"},{"key":"320_CR54","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2133.1992.tb14851.x","volume":"127","author":"T Ruzicka","year":"1992","unstructured":"Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. 1992;127:513\u20138.","journal-title":"Br J Dermatol"},{"key":"320_CR55","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"320_CR56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141\u201351.","journal-title":"Immunity"},{"key":"320_CR57","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways. Am J Clin Oncol. 2016;39:98\u2013106.","journal-title":"Am J Clin Oncol"},{"key":"320_CR58","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-4632.2011.04871.x","volume":"50","author":"VL Williams","year":"2011","unstructured":"Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. 2011;50:619\u201325.","journal-title":"Int J Dermatol"},{"key":"320_CR59","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","volume":"25","author":"LM Sedger","year":"2014","unstructured":"Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants\u2014past, present and future. Cytokine Growth Factor Rev. 2014;25:453\u201372.","journal-title":"Cytokine Growth Factor Rev"},{"key":"320_CR60","doi-asserted-by":"crossref","unstructured":"Qin J-Z, Bacon P, Panella J, et al. Low-dose UV-radiation sensitizes keratinocytes to TRAIL-induced apoptosis. J Cell Physiol. 2004; 200:155\u2013166","DOI":"10.1002\/jcp.20017"},{"key":"320_CR61","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0092-8674(93)90222-C","volume":"73","author":"LA Tartaglia","year":"1993","unstructured":"Tartaglia LA, Rothe M, Hu Y-F, et al. Tumor necrosis factor\u2019s cytotoxic activity is signaled by the p55 TNF receptor. Cell. 1993;73:213\u20136.","journal-title":"Cell"},{"key":"320_CR62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1191\/096120301675275538","volume":"10","author":"R Segal","year":"2001","unstructured":"Segal R, Dayan M, Zinger H, et al. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNF\u03b1 monoclonal antibody and by pentoxiphylline. Lupus. 2001;10:23\u201331.","journal-title":"Lupus"},{"key":"320_CR63","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.4049\/jimmunol.143.11.3470","volume":"143","author":"DC Brennan","year":"1989","unstructured":"Brennan DC, Yui MA, Wuthrich RP, et al. Tumor necrosis factor and IL-1 in New Zealand Black\/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol. 1989;143:3470\u20135.","journal-title":"J Immunol"},{"key":"320_CR64","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1016\/j.jaad.2005.11.1090","volume":"54","author":"R Norman","year":"2006","unstructured":"Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol. 2006;54:S139\u2013S142142.","journal-title":"J Am Acad Dermatol"},{"key":"320_CR65","first-page":"1283","volume":"9","author":"D Levine","year":"2010","unstructured":"Levine D, Switlyk SA, Gottlieb A. Cutaneous lupus erythematosus and anti-TNF-alpha therapy: a case report with review of the literature. J Drugs Dermatol. 2010;9:1283\u20137.","journal-title":"J Drugs Dermatol"},{"key":"320_CR66","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.crohns.2012.09.006","volume":"7","author":"P Eder","year":"2013","unstructured":"Eder P, Lykowska-Szuber L, Krela-Kazmierczak I, et al. The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn\u2019s disease\u2014an immunohistochemical study. J Crohn\u2019s Colitis. 2013;7:706\u201316.","journal-title":"J Crohn\u2019s Colitis"},{"key":"320_CR67","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/01.MIB.0000194185.69800.07","volume":"12","author":"C Shen","year":"2006","unstructured":"Shen C, Van Assche G, Rutgeerts P, et al. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis. 2006;12:22\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"320_CR68","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jaad.2006.05.004","volume":"55","author":"R Malaviya","year":"2006","unstructured":"Malaviya R, Sun Y, Tan JK, et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol. 2006;55:590\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"320_CR69","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1111\/1756-185X.12936","volume":"20","author":"M Al Izzi","year":"2017","unstructured":"Al Izzi M, Reda A. Cutaneous lupus erythematosus induced by golimumab therapy. Int J Rheum Dis. 2017;20:2159\u201361.","journal-title":"Int J Rheum Dis"},{"key":"320_CR70","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1084\/jem.20151255","volume":"213","author":"DX Nguyen","year":"2016","unstructured":"Nguyen DX, Ehrenstein MR. Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF\u2013TNF-RII binding in rheumatoid arthritis. J Exp Med. 2016;213:1241\u201353.","journal-title":"J Exp Med"},{"key":"320_CR71","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1046\/j.1523-1747.2000.00118.x","volume":"115","author":"VP Werth","year":"2000","unstructured":"Werth VP, Zhang W, Dortzbach K, et al. Association of a promoter polymorphism of tumor necrosis factor-\u03b1 with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription1. J Investig Dermatol. 2000;115:726\u201330.","journal-title":"J Investig Dermatol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00320-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-020-00320-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00320-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T18:05:54Z","timestamp":1696701954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-020-00320-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["320"],"URL":"https:\/\/doi.org\/10.1007\/s40268-020-00320-5","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,22]]},"assertion":[{"value":"22 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Christine Bolton, Yifan Chen, Ianthe R.M Schepel, Elinor Harriss, Silke C. Hofmann, Spencer Ellis, Alexander Clarke, Rachel Hawthorne,\u00a0Helena Wace, Blanca Martin, Joel Smith declare there are no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Provided in the electronic supplementary material and also from the corresponding author upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}